SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Anthony G. Visco, Linda Brubaker, J. Eric Jelovsek, Tracey S. Wilson, Peggy Norton, Halina M. Zyczynski, Cathie Spino, Larry Sirls, John N. Nguyen, David D. Rahn, Susie F. Meikle, Tracy L. Nolen, Adherence to Oral Therapy for Urgency Urinary Incontinence, Female Pelvic Medicine & Reconstructive Surgery, 2016, 22, 1, 24

    CrossRef

  2. 2
    Chun-Hou Liao, Sheng-Fu Chen, Hann-Chorng Kuo, Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study, Neurourology and Urodynamics, 2016, 35, 2
  3. 3
    Osamu YAMAGUCHI, Eiji UCHIDA, Naruhito HIGO, Hidenao MINAMI, Shigeo KOBAYASHI, Hiroyuki SATO, Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo, LUTS: Lower Urinary Tract Symptoms, 2016, 8, 1
  4. 4
    A. Sicras-Mainar, R. Navarro-Artieda, A. Ruiz-Torrejón, M. Sáez-Zafra, G. Coll-de Tuero, Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study, Actas Urológicas Españolas (English Edition), 2016,

    CrossRef

  5. 5
    Nisha Pindoria, Sachin Malde, Jennifer Nowers, Claire Taylor, Cornelius Kelleher, Arun Sahai, Persistence with mirabegron therapy for overactive bladder: A real life experience, Neurourology and Urodynamics, 2016, 35, 2
  6. 6
    Jing-Liang Chen, Sheng-Fu Chen, Yuan-Hong Jiang, Hann-Chorng Kuo, Practical points in the medical treatment of overactive bladder and nocturia in the elderly, Tzu Chi Medical Journal, 2016,

    CrossRef

  7. 7
    Marcus J. Drake, Roman Sokol, Karin Coyne, Zalmai Hakimi, Jameel Nazir, Julie Dorey, Monique Klaver, Klaudia Traudtner, Isaac A. Odeyemi, Matthias Oelke, Philip Kerrebroeck, Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study, BJU International, 2016, 117, 1
  8. 8
    Karen Noblett, Steven Siegel, Jeffrey Mangel, Tomas L. Griebling, Suzette E. Sutherland, Erin T. Bird, Craig Comiter, Daniel Culkin, Jason Bennett, Samuel Zylstra, Fangyu Kan, Kellie Chase Berg, Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder, Neurourology and Urodynamics, 2016, 35, 2
  9. 9
    Jonathan Duckett, Aswini Balachandran, Tolerability and persistence in a large, prospective case series of women prescribed mirabegron, International Urogynecology Journal, 2016,

    CrossRef

  10. 10
    Samuel Aballéa, Khaled Maman, Katia Thokagevistk, Jameel Nazir, Isaac A. O. Odeyemi, Zalmai Hakimi, Andy Garnham, Mondher Toumi, Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom, Clinical Drug Investigation, 2015, 35, 2, 83

    CrossRef

  11. 11
    Jameel Nazir, Lars Heemstra, Anke van Engen, Zalmai Hakimi, Cristina Ivanescu, Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia, BMC Urology, 2015, 15, 1

    CrossRef

  12. 12
    Jameel Nazir, Khaled Maman, Mohamed-Elmoctar Neine, Benjamin Briquet, Isaac A.O. Odeyemi, Zalmai Hakimi, Andy Garnham, Samuel Aballéa, Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom, Value in Health, 2015, 18, 6, 783

    CrossRef

  13. 13
    Marta Rossanese, Giacomo Novara, Ben Challacombe, Alessandro Iannetti, Prokar Dasgupta, Vincenzo Ficarra, Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB), BJU International, 2015, 115, 1
  14. 14
    Yasuhiro Wada, Hiromitsu Shirahashi, Taisuke Iwanami, Masami Ogawa, Seiji Nakano, Akifumi Morimoto, Ken-ichi Kasahara, Eiichi Tanaka, Yoshio Takada, Shigeki Ohashi, Mutsuhiro Mori, Satoshi Shuto, Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects, Journal of Medicinal Chemistry, 2015, 58, 15, 6048

    CrossRef

  15. 15
    Tulin Yildiz, Cenk M Yazici, Cagri Dogan, Muzeyyen Cetintas, Arzu Malak, Does patient education increase antimuscarinic treatment persistence in overactive bladder syndrome?, International Journal of Urological Nursing, 2015, 9, 2
  16. 16
    Tae Heon Kim, Myung-Soo Choo, Young-Joo Kim, Hyein Koh, Kyu-Sung Lee, Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome, Quality of Life Research, 2015,

    CrossRef

  17. 17
    Ganesh Thiagamoorthy, Linda Cardozo, Sushma Srikrishna, Drug therapy for an overactive bladder, Women's Health, 2015, 11, 4, 445

    CrossRef

  18. 18
    Zalmai Hakimi, Michelle Johnson, Jameel Nazir, Betina Blak, Isaac A.O. Odeyemi, Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data, Current Medical Research and Opinion, 2015, 31, 1, 43

    CrossRef

  19. 19
    Ganesh Thiagamoorthy, Ilias Giarenis, Linda Cardozo, Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome, Expert Opinion on Investigational Drugs, 2015, 24, 10, 1299

    CrossRef

  20. 20
    Jameel Nazir, John Posnett, Anna Walker, Isaac A. Odeyemi, Zalmai Hakimi, Andrew Garnham, Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service, Journal of Medical Economics, 2015, 18, 5, 390

    CrossRef

  21. 21
    Adrian Wagg, Amanda Darekar, Daniel Arumi, Vik Khullar, Matthias Oelke, Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study, Neurourology and Urodynamics, 2015, 34, 5
  22. 22
    Margaret Irwin, Lee Ann Johnson, Factors Influencing Oral Adherence: Qualitative Metasummary and Triangulation With Quantitative Evidence, Clinical Journal of Oncology Nursing, 2015, 19, 3, 6

    CrossRef

  23. 23
    R. A. Castro, R. M. Arruda, M. A. T. Bortolini, Female urinary incontinence: effective treatment strategies, Climacteric, 2015, 18, 2, 135

    CrossRef

  24. 24
    Murat Zor, Emin Aydur, Roger Roman Dmochowski, Flavoxate in urogynecology: an old drug revisited, International Urogynecology Journal, 2015, 26, 7, 959

    CrossRef

  25. 25
    X. Gamé, G. Karsenty, A. Ruffion, G. Amarenco, P. Ballanger, E. Chartier-Kastler, M. Cosson, P. Costa, B. Fatton, X. Deffieux, F. Haab, J.-F. Hermieu, L. Le Normand, C. Saussine, P. Denys, Hyperactivité vésicale idiopathique et BOTOX® : revue de la littérature, Progrès en Urologie, 2015, 25, 8, 461

    CrossRef

  26. 26
    S. Faithfull, A. Lemanska, P. Aslet, N. Bhatt, J. Coe, L. Drudge-Coates, M. Feneley, R. Glynn-Jones, M. Kirby, S. Langley, T. McNicholas, J. Newman, C. C. Smith, A. Sahai, E. Trueman, H. Payne, Integrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies, International Journal of Clinical Practice, 2015, 69, 10
  27. 27
    A. Alcántara Montero, Novedades en el tratamiento médico de la vejiga hiperactiva, SEMERGEN - Medicina de Familia, 2015,

    CrossRef

  28. 28
    A. Sicras-Mainar, R. Navarro-Artieda, A. Ruiz-Torrejón, M. Sáez-Zafra, G. Coll-de Tuero, Persistencia y medicación concomitante en pacientes con vejiga hiperactiva tratados con antimuscarínicos en atención primaria: estudio de base observacional, Actas Urológicas Españolas, 2015,

    CrossRef

  29. 29
    Steven Siegel, Karen Noblett, Jeffrey Mangel, Tomas L. Griebling, Suzette E. Sutherland, Erin T. Bird, Craig Comiter, Daniel Culkin, Jason Bennett, Samuel Zylstra, Kellie Chase Berg, Fangyu Kan, Christopher P. Irwin, Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder, Neurourology and Urodynamics, 2015, 34, 3
  30. 30
    Jerry G. Blaivas, Rajveer S. Purohit, Matthew S. Benedon, Gabriel Mekel, Michael Stern, Mubashir Billah, Kola Olugbade, Robert Bendavid, Vladimir Iakovlev, Safety considerations for synthetic sling surgery, Nature Reviews Urology, 2015, 12, 9, 481

    CrossRef

  31. 31
    Pamela Ellsworth, Jennifer Fantasia, Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder, Expert Opinion on Investigational Drugs, 2015, 24, 3, 413

    CrossRef

  32. 32
    Kirill V. Kosilov, Sergay A. Loparev, Marina A. Ivanovskaya, Liliya V. Kosilova, The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection, Arab Journal of Urology, 2015, 13, 3, 203

    CrossRef

  33. 33
    Matthias Oelke, Rajesh Shinghal, Angelina Sontag, Simin K. Baygani, Craig F. Donatucci, Time to Onset of Clinically Meaningful Improvement with Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Analysis of Data Pooled from 4 Pivotal, Double-Blind, Placebo Controlled Studies, The Journal of Urology, 2015, 193, 5, 1581

    CrossRef

  34. 34
    Mauro Gacci, Arcangelo Sebastianelli, Matteo Salvi, Riccardo Schiavina, Eugenio Brunocilla, Giacomo Novara, Cosimo De Nunzio, Andrea Tubaro, Matthias Oelke, Stavros Gravas, Marco Carini, Sergio Serni, Tolterodine in the Treatment of Male LUTS, Current Urology Reports, 2015, 16, 9

    CrossRef

  35. 35
    Yoshihisa Matsukawa, Shun Takai, Yasuhito Funahashi, Tokunori Yamamoto, Momokazu Gotoh, Urodynamic Evaluation of the Efficacy of Mirabegron on Storage and Voiding Functions in Women With Overactive Bladder, Urology, 2015, 85, 4, 786

    CrossRef

  36. 36
    W. Gibson, A. Athanasopoulos, H. Goldman, H. Madersbacher, D. Newman, J. Spinks, J. J. Wyndaele, A. Wagg, Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?, International Journal of Clinical Practice, 2014, 68, 9
  37. 37
    Khaled Maman, Samuel Aballea, Jameel Nazir, Katia Desroziers, Mohamed-Elmoctar Neine, Emad Siddiqui, Isaac Odeyemi, Zalmai Hakimi, Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison, European Urology, 2014, 65, 4, 755

    CrossRef

  38. 38
    Emilio Sacco, Riccardo Bientinesi, Daniele Tienforti, Marco Racioppi, Gaetano Gulino, Daniele D'Agostino, Matteo Vittori, Pierfrancesco Bassi, Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence, Expert Opinion on Drug Discovery, 2014, 9, 4, 433

    CrossRef

  39. 39
    Tomas L. Griebling, Epidemiology, Evaluation, and Treatment of Urinary Incontinence in Octogenarian Women, Current Bladder Dysfunction Reports, 2014, 9, 3, 242

    CrossRef

  40. 40
    Jasmina I. Ivanova, Eleanor Hayes-Larson, Rachael A. Sorg, Howard G. Birnbaum, Todd Berner, Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder, Journal of Medical Economics, 2014, 17, 10, 741

    CrossRef

  41. You have free access to this content41
    Momokazu Gotoh, Toshimitsu Kobayashi, Keizo Sogabe, Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q), International Journal of Urology, 2014, 21, 5
  42. 42
    X. Deffieux, B. Fatton, P. Denys, E. Chartier-Kastler, G. Amarenco, F. Haab, P. Costa, X. Game, G. Karsenty, C. Saussine, P. Ballanger, L. Le Normand, A. Ruffion, J.-F. Hermieu, M. Cosson, Injections intra-détrusoriennes de toxine botulinique pour l’hyperactivité vésicale idiopathique réfractaire de la femme, Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 2014, 43, 8, 572

    CrossRef

  43. 43
    Paul W. Veenboer, J.L.H. Ruud Bosch, Long-Term Adherence to Antimuscarinic Therapy in Everyday Practice: A Systematic Review, The Journal of Urology, 2014, 191, 4, 1003

    CrossRef

  44. 44
    Adrian Wagg, Vik Khullar, Martin C. Michel, Matthias Oelke, Amanda Darekar, Caty Ebel Bitoun, Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: Open-label extension of the SOFIA trial, Neurourology and Urodynamics, 2014, 33, 1
  45. 45
    Cara Tannenbaum, Kristina Johnell, Managing Therapeutic Competition in Patients with Heart Failure, Lower Urinary Tract Symptoms and Incontinence, Drugs & Aging, 2014, 31, 2, 93

    CrossRef

  46. 46
    Christopher R. Chapple, Linda Cardozo, Victor W. Nitti, Emad Siddiqui, Martin C. Michel, Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability, Neurourology and Urodynamics, 2014, 33, 1
  47. 47
    Umberto Leone Roberti Maggiore, Linda Cardozo, Simone Ferrero, Filomena Sileo, Alice Cola, Marco Torella, Nicola Colacurci, Massimo Candiani, Stefano Salvatore, Mirabegron in the treatment of overactive bladder, Expert Opinion on Pharmacotherapy, 2014, 15, 6, 873

    CrossRef

  48. 48
    W. Gibson, A. Wagg, New horizons: urinary incontinence in older people, Age and Ageing, 2014, 43, 2, 157

    CrossRef

  49. 49
    Christopher R. Chapple, Victor W. Nitti, Vik Khullar, Jean Jacques Wyndaele, Sender Herschorn, Philip van Kerrebroeck, Mary Beth Blauwet, Emad Siddiqui, Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder, World Journal of Urology, 2014, 32, 6, 1565

    CrossRef

  50. 50
    Martino Maria Zacche, Ilias Giarenis, Linda Cardozo, Phase II drugs that target cholinergic receptors for the treatment of overactive bladder, Expert Opinion on Investigational Drugs, 2014, 23, 10, 1365

    CrossRef

  51. 51
    C.R. Chapple, P. Abrams, K.-E. Andersson, P. Radziszewski, T. Masuda, M. Small, T. Kuwayama, S. Deacon, Phase II Study on the Efficacy and Safety of the EP1 Receptor Antagonist ONO-8539 for Nonneurogenic Overactive Bladder Syndrome, The Journal of Urology, 2014, 191, 1, 253

    CrossRef

  52. You have free access to this content52
    Osamu Yamaguchi, Eiji Marui, Hidehiro Kakizaki, Yukio Homma, Yasuhiko Igawa, Masayuki Takeda, Osamu Nishizawa, Momokazu Gotoh, Masaki Yoshida, Osamu Yokoyama, Narihito Seki, Yasushi Ikeda, Sumito Ohkawa, Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder, BJU International, 2014, 113, 6
  53. 53
    S. Wille, D. Tenholte, O.A. Cornely, N. Muthen, U.-H. Engelmann, J. Mehner, O. Eminaga, J. Herden, P. Schumacher, J. Paas, Prädiktion der Therapie der überaktiven Blase mittels katheterloser Langzeiturodynamik, Der Urologe, 2014, 53, 12, 1812

    CrossRef

  54. 54
    Sheng-Mou Hsiao, Shih-Cheng Liao, Chi-Hau Chen, Ting-Chen Chang, Ho-Hsiung Lin, Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects, Maturitas, 2014, 79, 4, 428

    CrossRef

  55. 55
    V. W. Nitti, C. R. Chapple, C. Walters, M. B. Blauwet, S. Herschorn, I. Milsom, S. Auerbach, P. Radziszewski, Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial, International Journal of Clinical Practice, 2014, 68, 8
  56. 56
    A. Wagg, L. Cardozo, V. W. Nitti, D. Castro-Diaz, S. Auerbach, M. B. Blauwet, E. Siddiqui, The efficacy and tolerability of the  3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients, Age and Ageing, 2014, 43, 5, 666

    CrossRef

  57. 57
    Niels V. Johnsen, David J. Osborn, Roger R. Dmochowski, The role of electrical stimulation techniques in the management of the male patient with urgency incontinence, Current Opinion in Urology, 2014, 24, 6, 560

    CrossRef

  58. 58
    William Gibson, Adrian Wagg, Urinary incontinence in the frail elderly: what do we still need to learn?, Clinical Practice, 2014, 11, 4, 431

    CrossRef

  59. 59
    Dudley Robinson, Linda Cardozowan, Urinary incontinence in the young woman: treatment plans and options available, Women's Health, 2014, 10, 2, 201

    CrossRef

  60. 60
     Mirabegron for overactive bladder syndrome, Drug and Therapeutics Bulletin, 2013, 51, 8, 90

    CrossRef

  61. 61
    Kirill Vladimirovich Kosilov, Sergey Alexandrovich Liparev, Yuliya Igorevna Gainullina, Marina Anatoleyevna Ivanovskaya, Liliya Victorovna Kosilova, A Novel Approach to Managing Intravesical Magnetic Beads, UroToday International Journal, 2013, 06, 06

    CrossRef

  62. You have free access to this content62
    Kang Jun Cho, Joon Chul Kim, Biomarkers for lower urinary tract dysfunction, International Journal of Urology, 2013, 20, 1
  63. 63
    Vik Khullar, Linda Cardozo, Con J. Kelleher, Timothy Hall, John Ryan, Caty Ebel Bitoun, Amanda Darekar, Daniel Arumi, Adrian Wagg, Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder, BJU International, 2013, 112, 6
  64. 64
    Vik Khullar, Gerard Amarenco, Javier C. Angulo, Javier Cambronero, Kjetil Høye, Ian Milsom, Piotr Radziszewski, Tomasz Rechberger, Peter Boerrigter, Ted Drogendijk, Marianne Wooning, Christopher Chapple, Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial, European Urology, 2013, 63, 2, 283

    CrossRef

  65. 65
    Vik Khullar, Javier Cambronero, Javier C Angulo, Marianne Wooning, Mary Blauwet, Caroline Dorrepaal, Nancy E Martin, Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial, BMC Urology, 2013, 13, 1, 45

    CrossRef

  66. 66
    J.C. Angulo, V. Khullar, V.W. Nitti, E. Siddiqui, Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder, Actas Urológicas Españolas (English Edition), 2013, 37, 10, 640

    CrossRef

  67. 67
    J.C. Angulo, V. Khullar, V.W. Nitti, E. Siddiqui, Evidencia disponible acerca del uso del agonista β3-adrenoceptor selectivo mirabegrón para el tratamiento de la vejiga hiperactiva, Actas Urológicas Españolas, 2013, 37, 10, 640

    CrossRef

  68. 68
    Umberto Leone Roberti Maggiore, Carolina Scala, Pier Luigi Venturini, Simone Ferrero, Imidafenacin for the treatment of overactive bladder, Expert Opinion on Pharmacotherapy, 2013, 14, 10, 1383

    CrossRef

  69. 69
    Toshiki Hatanaka, Masashi Ukai, Mai Watanabe, Akiyoshi Someya, Akiyoshi Ohtake, Masanori Suzuki, Koji Ueshima, Shuichi Sato, Masao Sasamata, In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats, Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 3, 247

    CrossRef

  70. 70
    R. Caremel, J.-N. Cornu, J. Kerdraon, E. Castel-Lacanal, C. Bastide, F. Bruyere, L. Guy, G. Karsenty, Les médicaments de la vessie, Progrès en Urologie, 2013, 23, 15, 1271

    CrossRef

  71. 71
    V. W. Nitti, V. Khullar, P. Kerrebroeck, S. Herschorn, J. Cambronero, J. C. Angulo, M. B. Blauwet, C. Dorrepaal, E. Siddiqui, N. E. Martin, Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies, International Journal of Clinical Practice, 2013, 67, 7
  72. 72
    Jamie Bartley, Jason Gilleran, Kenneth Peters, Neuromodulation for overactive bladder, Nature Reviews Urology, 2013,

    CrossRef

  73. 73
    Dudley Robinson, Ilias Giarenis, Linda Cardozo, New developments in the medical management of overactive bladder, Maturitas, 2013, 76, 3, 225

    CrossRef

  74. 74
    Eu Kiang Sharon Yeo, Hashim Hashim, Paul Abrams, New therapies in the treatment of overactive bladder, Expert Opinion on Emerging Drugs, 2013, 18, 3, 319

    CrossRef

  75. 75
    Dudley Robinson, Ilias Giarenis, Linda Cardozo, The medical management of refractory Overactive Bladder, Maturitas, 2013, 74, 4, 386

    CrossRef

  76. 76
    J.-N. Cornu, F. Haab, Traitements pharmacologiques de l’hyperactivité vésicale idiopathique : revue de la littérature, Progrès en Urologie, 2013, 23, 4, 227

    CrossRef

  77. 77
    M.A. Jiménez, J. Cambronero, Validación de la versión española del cuestionario «Beneficio, satisfacción y disposición para continuar el tratamiento» en pacientes con vejiga hiperactiva, Actas Urológicas Españolas, 2013, 37, 8, 473

    CrossRef

  78. 78
    M.A. Jiménez, J. Cambronero, Validation of the Spanish Version of the Questionnaire “Benefit, Satisfaction and Willingness to Continue the Treatment” in patients with overactive bladder, Actas Urológicas Españolas (English Edition), 2013, 37, 8, 473

    CrossRef

  79. 79
    Karl-Erik Andersson, β3-Receptor Agonists for Overactive Bladder—New Frontier or More of the Same?, Current Urology Reports, 2013, 14, 5, 435

    CrossRef

  80. 80
    Nora Buser, Sandra Ivic, Thomas M. Kessler, Alfons G.H. Kessels, Lucas M. Bachmann, Efficacy and Adverse Events of Antimuscarinics for Treating Overactive Bladder: Network Meta-analyses, European Urology, 2012, 62, 6, 1040

    CrossRef

  81. 81
    Nadir I. Osman, Christopher R. Chapple, Antimuscarinics,
  82. 82
    Jack C. Hou, Philippe E. Zimmern, Timing for evaluation,